Pharmafile Logo

Join Genesis Research Group’s October webinar: ‘From scoping to systematic: Choosing the right literature review for your evidence needs’.

On Tuesday, 6 October 2026, Genesis Research Group’s evidence synthesis, HEOR, and evidence planning teams will be presenting an expert webinar on the topic of selecting the right literature review.

Literature review webinar promo

 

On Tuesday, 6 October 2026, Genesis Research Group’s evidence synthesis, HEOR, and evidence planning teams will be presenting a webinar in partnership with the The Evidence Base. The topic of the webinar is ‘From scoping to systematic: Choosing the right literature review for your evidence needs‘.

Overview

Navigate the literature review spectrum and gain practical insight into selecting the most appropriate review approach for your evidence needs.

Whether informing internal strategy discussions or supporting HTA submissions, literature reviews are used to answer a wide range of evidence needs across the pharmaceutical industry. From scoping and targeted to fully systematic literature reviews, understanding where different methodologies fit along the evidence synthesis spectrum is key to selecting the right approach.

This webinar will explore the spectrum of literature review methodologies, examine how different review types support varying evidence requirements and decision contexts, and discuss their role within integrated evidence generation planning (IEGP) to support more informed evidence decisions across the product lifecycle.

Designed for pharma and biotech professionals who plan, commission, or act on literature reviews, from HEOR and market access to medical affairs and evidence generation leads.

Learning Objectives

  • Become familiar with types of literature reviews and the terminology used to define them.
  • Understand how different literature review approaches vary in purpose, rigor, and resource requirements.
  • Recognize the trade-offs between breadth, speed, reproducibility, and methodological rigor.
  • Identify the strengths, limitations, and appropriate applications of different review types across common use cases.
  • Understand how different literature review methodologies fit within IEGP and support varying evidence requirements.

 

Register to join live or receive the recording

 

Speakers

Zarmina Khankhel
Senior Director, Evidence Synthesis, Genesis Research Group
Zarmina has 15+ years experience in HEOR and RWE consulting. She focuses on both qualitative (e.g., systematic and non-systematic literature reviews) and quantitative (e.g., feasibility assessment, meta-analysis, indirect treatment comparisons including network meta-analysis) evidence synthesis activities. In her role at Genesis, she leads the Evidence Synthesis team on global and region-specific projects across a wide range of disease areas and on projects supporting various needs including dossier development, data landscape assessment, evidence gap analysis, HTA, internal strategy support, modeling inputs, publication development and strategy, among others.

Samara Ferguson
Vice President, Head of HEOR, Genesis Research Group
Samara has 30+ years of experience in HEOR and market access across consulting and industry roles. Her expertise spans the full spectrum of market access and evidence strategy, including payer evidence generation, value proposition development, global value dossiers, economic modeling, and HTA submissions. In her role at Genesis, she leads the HEOR team, supporting pharmaceutical and biotech companies in communicating asset value across global and regional markets and helping clients navigate complex reimbursement and payer decision-making environments.

Priti Jhingran
Vice President, Head of HEOR Strategy & Partnerships, Genesis Research Group
Priti has 30+ years of experience in the pharmaceutical industry across consulting and industry roles. A recognized leader in market access, HTA, and evidence strategy, she has helped organizations understand evidence needs and develop approaches that inform access and reimbursement decisions across US and global markets. Priti has led enterprise-wide initiatives focused on value, evidence, and outcomes, supported the launch of more than 15 pharmaceutical products, and built high-performing Health Outcomes teams. She is a frequent speaker and author with more than 75 peer-reviewed publications in health economics, policy, and services research.

This content was provided by Genesis Research Group

Company Details

 Latest Content from  Genesis Research Group 

Genesis Research Group launches Keystone IEGP platform at ISPOR Europe 2026

Genesis Research Group (Genesis) launches Keystone, its modular platform for Integrated Evidence Generation Planning (IEGP), at ISPOR Europe 2026.

Access The Vector Issue 3: 15 payers describe the likely affect of EU General Pharmaceutical Legislation on orphan drug strategy

In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they believe the new EU General Pharmaceutical Legislation will…

On GLOBE Final Rule

The publication of the GLOBE Final Rule provides important clarity on the administration’s approach to MFN pricing and what it could mean for pharmaceutical pricing, reimbursement, and access strategy globally….

Join Genesis Research Group’s October webinar: ‘From scoping to systematic: Choosing the right literature review for your evidence needs’.

On Tuesday, 6 October 2026, Genesis Research Group’s evidence synthesis, HEOR, and evidence planning teams will be presenting an expert webinar on the topic of selecting the right literature review.

Genesis Research Group Appoints Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR

Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence…

Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026

Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations and eligible researchers. “Run it…

MFN Pricing Is Moving Fast – Here’s What Matters

With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it’s a lot to digest. In a new…

ISPOR’s 2026–2027 HEOR Trends report: The Era of Evidence Judgment

In response to ISPOR’s recently published 2026-2027 HEOR Trends, David Miller, CEO, Genesis Research Group, suggests that we’re no longer being evaluated on our ability to produce data, but on…

Tim Wright Updates ISPOR Europe MFN Pricing Presentation in New Interview

At ISPOR Europe in Glasgow, there were literal queues around the block for Tim Wright’s HEOR Theater presentation ‘MFN Pricing: More Fun to Navigate – A European Roadmap to Success,’ with potentially…

Genesis Research Group contributes strong scientific program to ISPOR Europe and warmly invites visitors to booth 212

Genesis Research Group is proud to be attending ISPOR Europe 2025 in Glasgow from 10-12th November with a strong scientific program that includes an HEOR Theater session, contributions to 10…